{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T01:15:12Z","timestamp":1788225312245,"version":"build-2803163510"},"reference-count":53,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.clinre.2026.102880","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T23:44:11Z","timestamp":1782949451000},"page":"102880","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and efficacy of hepatic arterial infusion chemotherapy combined with camrelizumab and apatinib for advanced hepatocellular carcinoma: A retrospective clinical analysis"],"prefix":"10.1016","volume":"50","author":[{"given":"Ruijun","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zexin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.clinre.2026.102880_bib0001","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1053\/j.gastro.2016.11.048","article-title":"Liver cancer cell of origin, molecular class, and effects on patient prognosis","volume":"152","author":"Sia","year":"2017","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.clinre.2026.102880_bib0002","doi-asserted-by":"crossref","first-page":"256","DOI":"10.21037\/jgo.2016.09.07","article-title":"Hepatocellular carcinoma (HCC): beyond sorafenib-chemotherapy","volume":"8","author":"Kim","year":"2017","journal-title":"J Gastrointest Oncol"},{"issue":"2","key":"10.1016\/j.clinre.2026.102880_bib0003","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.suronc.2016.03.002","article-title":"Hepatocellular carcinoma: from diagnosis to treatment","volume":"25","author":"Grandhi","year":"2016","journal-title":"Surg Oncol"},{"issue":"10127","key":"10.1016\/j.clinre.2026.102880_bib0004","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.clinre.2026.102880_bib0005","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.3390\/ijms20061406","article-title":"Exosomes and hepatocellular carcinoma: from bench to bedside","volume":"20","author":"Sasaki","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.clinre.2026.102880_bib0006","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41575-021-00438-0","article-title":"Advances in immunotherapy for hepatocellular carcinoma","volume":"18","author":"Sangro","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.clinre.2026.102880_bib0007","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.clinre.2026.102880_bib0008","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clinre.2026.102880_bib0009","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1158\/1078-0432.CCR-18-2484","article-title":"Anti-PD-1 antibody SHR-1210 combined with Apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open-label, dose escalation and expansion study","volume":"25","author":"Xu","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.clinre.2026.102880_bib0010","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S1470-2045(20)30011-5","article-title":"Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial","volume":"21","author":"Qin","year":"2020","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.clinre.2026.102880_bib0011","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S2468-1253(21)00109-6","article-title":"Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"6","author":"Qin","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.clinre.2026.102880_bib0012","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004656","article-title":"Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial","volume":"10","author":"Xia","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clinre.2026.102880_bib0013","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.clinre.2026.102880_bib0014","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41575-020-00395-0","article-title":"Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma","volume":"18","author":"Llovet","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"21","key":"10.1016\/j.clinre.2026.102880_bib0015","doi-asserted-by":"crossref","first-page":"8165","DOI":"10.3390\/ijms21218165","article-title":"Recent updates of transarterial chemoembolilzation in hepatocellular carcinoma","volume":"21","author":"Chang","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.clinre.2026.102880_bib0016","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1159\/000439290","article-title":"Subclassification of BCLC B stage hepatocellular carcinoma and treatment strategies: proposal of modified Bolondi's Subclassification (Kinki Criteria)","volume":"33","author":"Kudo","year":"2015","journal-title":"Dig Dis"},{"issue":"1","key":"10.1016\/j.clinre.2026.102880_bib0017","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00270-014-0907-0","article-title":"Transarterial chemoembolization for hepatocellular carcinoma with a new generation of beads: clinical-radiological outcomes and safety profile","volume":"38","author":"Spreafico","year":"2015","journal-title":"Cardiovasc Interv Radiol"},{"issue":"9","key":"10.1016\/j.clinre.2026.102880_bib0018","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/jjco\/hyz069","article-title":"Sorafenib versus hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis","volume":"49","author":"Zhuang","year":"2019","journal-title":"Jpn J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clinre.2026.102880_bib0019","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/jgh.16088","article-title":"Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib alone for advanced hepatocellular carcinoma: a systematic review and meta-analysis","volume":"38","author":"Long","year":"2023","journal-title":"J Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.clinre.2026.102880_bib0020","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jvir.2021.06.008","article-title":"Hepatic artery infusion chemotherapy using Fluorouracil, Leucovorin, and oxaliplatin versus transarterial chemoembolization as initial treatment for locally advanced hepatocellular carcinoma: a propensity score-matching analysis","volume":"32","author":"Li","year":"2021","journal-title":"J Vasc Interv Radiol"},{"issue":"Suppl 1","key":"10.1016\/j.clinre.2026.102880_bib0021","doi-asserted-by":"crossref","first-page":"S157","DOI":"10.1016\/j.acra.2021.01.024","article-title":"Hepatic arterial infusion chemotherapy with modified FOLFOX as an alternative treatment option in advanced hepatocellular carcinoma patients with failed or unsuitability for transarterial chemoembolization","volume":"28","author":"Hsu","year":"2021","journal-title":"Acad Radiol"},{"issue":"1","key":"10.1016\/j.clinre.2026.102880_bib0022","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s40880-017-0251-2","article-title":"Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study","volume":"36","author":"He","year":"2017","journal-title":"Chin J Cancer"},{"issue":"7","key":"10.1016\/j.clinre.2026.102880_bib0023","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamaoncol.2019.0250","article-title":"Sorafenib plus hepatic arterial infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial","volume":"5","author":"He","year":"2019","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.clinre.2026.102880_bib0024","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1186\/s12885-021-08858-6","article-title":"Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study","volume":"21","author":"Chen","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clinre.2026.102880_bib0025","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.618206","article-title":"Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors plus Lenvatinib versus PD-1 inhibitors plus Lenvatinib for advanced hepatocellular carcinoma","volume":"11","author":"Mei","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.clinre.2026.102880_bib0026","doi-asserted-by":"crossref","first-page":"8669","DOI":"10.1007\/s00330-023-09754-2","article-title":"Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study","volume":"33","author":"Jin","year":"2023","journal-title":"Eur Radiol"},{"key":"10.1016\/j.clinre.2026.102880_bib0027","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211002720","article-title":"Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma","volume":"13","author":"He","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.clinre.2026.102880_bib0028","first-page":"52","volume":"30","author":"Lencioni","year":"2010"},{"issue":"1","key":"10.1016\/j.clinre.2026.102880_bib0029","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the common terminology criteria for adverse events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"issue":"4","key":"10.1016\/j.clinre.2026.102880_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2021.101851","article-title":"Effect of camrelizumab plus transarterial chemoembolization on massive hepatocellular carcinoma","volume":"46","author":"Zhang","year":"2022","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"6","key":"10.1016\/j.clinre.2026.102880_bib0031","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3892\/ol.2021.12748","article-title":"Predictive effects of preoperative serum CA125 and AFP levels on post-hepatectomy survival in patients with hepatitis B-related hepatocellular carcinoma","volume":"21","author":"Qin","year":"2021","journal-title":"Oncol Lett"},{"key":"10.1016\/j.clinre.2026.102880_bib0032","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2147\/JHC.S376607","article-title":"Predictive value of preoperative serum AFP, CEA, and CA19-9 levels in patients with single small hepatocellular carcinoma: retrospective study","volume":"Volume 9","author":"Gan","year":"2022","journal-title":"J Hepatocell Carcinoma"},{"issue":"9","key":"10.1016\/j.clinre.2026.102880_bib0033","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nrclinonc.2014.122","article-title":"Treatment of intermediate-stage hepatocellular carcinoma","volume":"11","author":"Forner","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"issue":"51","key":"10.1016\/j.clinre.2026.102880_bib0034","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000032390","article-title":"HAIC versus TACE for patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis","volume":"101","author":"Liu","year":"2022","journal-title":"Medicine"},{"key":"10.1016\/j.clinre.2026.102880_bib0035","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2147\/JHC.S298538","article-title":"Anti-PD-1 immunotherapy improves the efficacy of hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma","volume":"Volume 8","author":"Mei","year":"2021","journal-title":"J Hepatocell Carcinoma"},{"issue":"1","key":"10.1016\/j.clinre.2026.102880_bib0036","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13045-019-0794-6","article-title":"Emerging agents and regimens for hepatocellular carcinoma","volume":"12","author":"Zhu","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"4","key":"10.1016\/j.clinre.2026.102880_bib0037","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3892\/ol.2021.12540","article-title":"Clinical outcomes and influencing factors of PD-1\/PD-L1 in hepatocellular carcinoma","volume":"21","author":"Wang","year":"2021","journal-title":"Oncol Lett"},{"issue":"1","key":"10.1016\/j.clinre.2026.102880_bib0038","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/s12885-022-09325-6","article-title":"Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma","volume":"22","author":"Guo","year":"2022","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.clinre.2026.102880_bib0039","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1158\/2326-6066.CIR-17-0640","article-title":"Low-dose apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1\/PD-L1 blockade in lung cancer","volume":"7","author":"Zhao","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"12","key":"10.1016\/j.clinre.2026.102880_bib0040","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1111\/liv.14223","article-title":"Biology and significance of alpha-fetoprotein in hepatocellular carcinoma","volume":"39","author":"Galle","year":"2019","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.clinre.2026.102880_bib0041","first-page":"314","article-title":"Serum biomarkers AFP, CEA and CA19-9 combined detection for early diagnosis of hepatocellular carcinoma","volume":"48","author":"Edoo","year":"2019","journal-title":"Iran J Public Health"},{"issue":"10","key":"10.1016\/j.clinre.2026.102880_bib0042","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1007\/s00432-020-03331-6","article-title":"Effects of alpha-fetoprotein on the occurrence and progression of hepatocellular carcinoma","volume":"146","author":"Zheng","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"10.1016\/j.clinre.2026.102880_bib0043","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-12834-1","article-title":"The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma","volume":"7","author":"Bai","year":"2017","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.clinre.2026.102880_bib0044","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.21873\/anticanres.11430","article-title":"Elevated preoperative serum CEA level is associated with poor prognosis in patients with hepatocellular carcinoma through the epithelial-mesenchymal transition","volume":"37","author":"Yoshikawa","year":"2017","journal-title":"Anticancer Res"},{"issue":"2","key":"10.1016\/j.clinre.2026.102880_bib0045","doi-asserted-by":"crossref","DOI":"10.1038\/ctg.2014.22","article-title":"Elevated CA19-9 is associated with increased mortality In A prospective cohort of hepatocellular carcinoma patients","volume":"6","author":"Hsu","year":"2015","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.clinre.2026.102880_bib0046","article-title":"A novel therapeutic strategy of combined camrelizumab and apatinib for the treatment of advanced hepatocellular carcinoma","volume":"13","author":"Yang","year":"2023","journal-title":"Front Oncol"},{"issue":"17","key":"10.1016\/j.clinre.2026.102880_bib0047","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.2217\/imt-2021-0192","article-title":"Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma","volume":"13","author":"Liu","year":"2021","journal-title":"Immunotherapy"},{"issue":"6","key":"10.1016\/j.clinre.2026.102880_bib0048","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1158\/1078-0432.CCR-17-2439","article-title":"Safety, activity, and biomarkers of SHR-1210, an Anti-PD-1 antibody, for patients with advanced esophageal carcinoma","volume":"24","author":"Huang","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.clinre.2026.102880_bib0049","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1200\/JCO.2017.74.9846","article-title":"Safety and antitumor activity of the anti-programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma","volume":"36","author":"Doi","year":"2018","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clinre.2026.102880_bib0050","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/jjco\/hyx180","article-title":"Chemotherapy for hepatocellular carcinoma: current status and future perspectives","volume":"48","author":"Ikeda","year":"2018","journal-title":"Jpn J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clinre.2026.102880_bib0051","doi-asserted-by":"crossref","DOI":"10.1002\/onco.13797","article-title":"Safety and feasibility of radiotherapy plus Camrelizumab for locally advanced esophageal squamous cell carcinoma","volume":"26","author":"Zhang","year":"2021","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.clinre.2026.102880_bib0052","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s41392-023-01663-6","article-title":"Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II study","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.clinre.2026.102880_bib0053","doi-asserted-by":"crossref","DOI":"10.4251\/wjgo.v17.i1.99834","article-title":"Advanced hepatocellular carcinoma treatment strategies: are transarterial approaches leading the way?","volume":"17","author":"Patauner","year":"2025","journal-title":"World J Gastrointest Oncol"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740126001269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740126001269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:46:28Z","timestamp":1788223588000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740126001269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":53,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2210740126001269"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2026.102880","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of hepatic arterial infusion chemotherapy combined with camrelizumab and apatinib for advanced hepatocellular carcinoma: A retrospective clinical analysis","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2026.102880","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"102880"}}